Company press releases

Displaying 2551 - 2565 of 2565 results
Released Company Title Industry Topic
17 Apr 2024
16:09 CEST 		EMBENTION SISTEMAS INTELIGENTES SA Embention partners with Amazon Prime Air 50202040 Electronic Equipment: Other Alliances and agreements
17 Apr 2024
10:00 CEST 		ATOS CEA and Eviden Launch Phase 2 of the EXA1 Supercomputer Program 10101010 Computer Services -
17 Apr 2024
10:00 CEST 		ATOS Le CEA et Eviden lancent la phase 2 du programme de supercalculateur EXA1 10101010 Computer Services -
17 Apr 2024
08:30 CEST 		VINCI VINCI to acquire the majority shareholding in Edinburgh Airport 50101010 Construction Corporate life
17 Apr 2024
08:30 CEST 		VINCI Acquisition par VINCI d’une participation majoritaire dans l’aéroport d’Édimbourg 50101010 Construction Corporate life
17 Apr 2024
08:00 CEST 		ORPEA EMEIS POURSUIT SA REFONDATION:Résultats annuels consolidés d’ORPEA S.A. 20101010 Health Care Facilities Income
17 Apr 2024
08:00 CEST 		MICHELIN Michelin : Déclaration des transactions sur actions propres - 17/04/2024 40101015 Tires Share history
17 Apr 2024
08:00 CEST 		ORPEA EMEIS PURSUES ITS REFOUNDATION:2023 Consolidated Financial Results of ORPEA S.A. 20101010 Health Care Facilities Income
17 Apr 2024
08:00 CEST 		MICHELIN Michelin : Disclosure of trading in own shares - April 17th 2024 40101015 Tires Share history
17 Apr 2024
07:45 CEST 		AFYREN AFYREN s’engage pour le Responsible Care® et reçoit un trophée dans la catégorie « Sociétal » 55201020 Specialty Chemicals Meetings / events
17 Apr 2024
07:45 CEST 		AFYREN AFYREN Commits to Responsible Care® and Receives a Trophy in the "Societal" Category 55201020 Specialty Chemicals Meetings / events
17 Apr 2024
07:00 CEST 		SANOFI Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis 20103015 Pharmaceuticals Other subject
17 Apr 2024
07:00 CEST 		SANOFI Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques 20103015 Pharmaceuticals Other subject
17 Apr 2024
00:10 CEST 		AXWAY SOFTWARE Axway Software : Déclaration des transactions sur actions propres 10101015 Software Other subject
17 Apr 2024
00:10 CEST 		AXWAY SOFTWARE Axway Software: Disclosure of Transactions in Own Shares 10101015 Software Other subject